CN Patent

CN115322794B — Glp-1和fgf21的融合蛋白的缀合物

Assigned to Beijing Zhipeptide Biomedical Technology Co ltd · Expires 2025-09-19 · 1y expired

What this patent protects

本公开提供了包含GLP‑1、多肽接头和FGF21的多肽的缀合物。还提供了包含其的药物组合物和治疗疾病的方法。

USPTO Abstract

本公开提供了包含GLP‑1、多肽接头和FGF21的多肽的缀合物。还提供了包含其的药物组合物和治疗疾病的方法。

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CN115322794B
Jurisdiction: CN
Classification: —
Expires: 2025-09-19
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Zhipeptide Biomedical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.